Seres Therapeutics Inc 's Cash & cash equivalent grew by 12.4 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Seres Therapeutics Inc 's Quick Ratio to 0.84, Quick Ratio remained below Seres Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 371 other companies have achieved higher Quick Ratio than Seres Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1469 to 2201.

Explain Quick Ratio?
How much Cash & cash equivalents MCRB�s has?
What are MCRB�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MCRB/financial-strength

https://api.csimarket.com/api/v1/companies/MCRB/fundamentals

https://api.csimarket.com/api/v1/companies/MCRB/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

MCRB Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-6.85 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-63.21 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.84	Subscribe	Subscribe	Subscribe	Subscribe
MCRB's Total Ranking	# 2201	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	4.3 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	12.4 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 372
Healthcare Sector	# 676
Overall Market	# 2201

Quick Ratio Statistics
High	Average	Low
56.71	12.6	0.66
(Dec 31 2020)		(Jun 30 2024)

Financial Statements
Seres Therapeutics Inc 's Current Liabilities	$ 21 Millions	Visit MCRB's Balance sheet
Seres Therapeutics Inc 's Cash & cash equivalent	$ 18 Millions	Visit MCRB's Balance sheet
Source of MCRB's Sales		Visit MCRB's Sales by Geography

Cumulative Seres Therapeutics Inc 's Quick Ratio

MCRB's Quick Ratio for the trailling 12 Months

MCRB Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-36.79 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-40.48 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.37	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3854	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-1.89 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-21.69 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to MCRB Financial Strength Comparisons >> Go to Compare MCRB Quick Ratio to its Competitors

News about Seres Therapeutics Inc Quick Ratio

Seres Therapeutics Makes Significant Capital Infusions, Retires Debt, and Extends Cash Runway Into 2025

Seres Therapeutics, a leading microbiome therapeutics company, has announced its plans to secure capital infusions that will enable the company to retire its debt completely and extend its cash runway into the fourth quarter of 2025. These plans are contingent upon deal closure and the company s performance under a transition services agreement. Analyzing the recent increase in Current Liabilities and its impact on Seres Therapeutics Quick Ratio will provide us with important insights into the company s financial health and stability.

1. Capital Infusions and Debt Retirement:
Through a series of anticipated capital infusions, including an upfront payment, Seres Therapeutics aims to effectively retire its debt burden. This strategic move will alleviate the financial strain on the company and allow it to focus on its core business operations and growth prospects. By reducing debt, Seres Therapeutics can allocate its resources more efficiently towards advancing its innovative microbiome therapies.

On the trailing twelve months basis In spite of the year on year decrease in MCRB's Current Liabilities to $20.89 millions, cumulative Quick Ratio to 1.37 below the MCRB average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 433 other companies have achieved higher Quick Ratio than Seres Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 3854, from total ranking during the twelve months ending second quarter 2026 at 3916.

Explain Quick Ratio?
How much Cash & cash equivalents MCRB�s has?
What are MCRB�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 434
Healthcare Sector	# 886
Within the Market	# 3854

trailing twelve months Quick Ratio Statistics
High	Average	Low
11.1	2.26	0.9
(Dec 31 2015)		(Dec 31 2024)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Pacira Biosciences inc	2.31	$ 295.577 Millions	$ 128.209 Millions
Dogwood Therapeutics inc	2.28	$ 4.948 Millions	$ 2.174 Millions
Ardelyx inc	2.23	$ 285.338 Millions	$ 127.805 Millions
Schrodinger Inc	2.20	$ 366.358 Millions	$ 166.292 Millions
Stoke Therapeutics Inc	2.19	$ 107.271 Millions	$ 48.977 Millions
Maravai Lifesciences Holdings Inc	2.14	$ 73.023 Millions	$ 34.160 Millions
Ernexa Therapeutics Inc	2.13	$ 5.575 Millions	$ 2.614 Millions
Madrigal Pharmaceuticals Inc	2.12	$ 962.387 Millions	$ 454.244 Millions
Puma Biotechnology Inc	2.09	$ 108.575 Millions	$ 51.971 Millions
Corcept Therapeutics Inc	2.09	$ 370.703 Millions	$ 177.675 Millions
Dianthus Therapeutics Inc	1.95	$ 55.686 Millions	$ 28.515 Millions
Xeris Biopharma Holdings Inc	1.95	$ 262.164 Millions	$ 134.479 Millions
Ars Pharmaceuticals Inc	1.95	$ 138.354 Millions	$ 70.995 Millions
Lite Strategy Inc	1.92	$ 4.281 Millions	$ 2.234 Millions
Mineralys Therapeutics Inc	1.91	$ 101.273 Millions	$ 53.075 Millions
Amarin Corp Plcuk	1.85	$ 323.379 Millions	$ 175.136 Millions
Mustang Bio inc	1.80	$ 14.276 Millions	$ 7.947 Millions
Biovie Inc	1.78	$ 7.733 Millions	$ 4.350 Millions
Alnylam Pharmaceuticals Inc	1.74	$ 3,587.255 Millions	$ 2,063.006 Millions
Insmed Inc	1.73	$ 1,146.626 Millions	$ 662.181 Millions
Nkarta Inc	1.72	$ 48.354 Millions	$ 28.072 Millions
Mannkind Corporation	1.67	$ 181.525 Millions	$ 108.524 Millions
Verastem Inc	1.67	$ 172.801 Millions	$ 103.328 Millions
Agios Pharmaceuticals Inc	1.66	$ 128.549 Millions	$ 77.588 Millions
Bridgebio Pharma Inc	1.57	$ 1,538.855 Millions	$ 977.237 Millions
Arcutis Biotherapeutics Inc	1.51	$ 259.460 Millions	$ 172.357 Millions
Regeneron Pharmaceuticals Inc	1.50	$ 9,301.100 Millions	$ 6,202.100 Millions
Emergent Biosolutions Inc	1.44	$ 175.700 Millions	$ 122.000 Millions
Compass Pathways Plc	1.36	$ 443.979 Millions	$ 325.863 Millions
Sarepta Therapeutics Inc	1.34	$ 878.776 Millions	$ 656.353 Millions

Date modified: 2026-11-05T10:01:53+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.